Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab

被引：0
|
作者：
Cioppa, Vittoria [1 ]
Lazzeri, Laura [1 ]
Carraro, Andrea [1 ]
De Piano, Ernesto [1 ]
Falcinelli, Francesca [1 ]
Galluzzo, Marco [2 ]
Pallotta, Sabatino [3 ]
De Pita, Ornella [3 ]
Russo, Filomena [3 ]
机构：
[1] Univ Siena, S Maria Scotte Hosp, Dept Med Surg & Neurol Sci, Dermatol Sect, Siena, Italy
[2] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy
[3] Dermatol Res Hosp, IDI IRCCS, Rome, Italy
来源：
DERMATITIS | 2024年 / 35卷
关键词：
D O I：
10.1089/derm.2023.0052
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    Smith, Brandon I.
    Engel, Priya
    Wu, Jashin
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24): : 2299 - 2300
  • [42] Long-term dupilumab treatment for 100 weeks reduces serum TARC and total IgE in patients with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Thaci, D.
    Bissonnette, R.
    Deleuran, M.
    Harel, S.
    Chen, Z.
    Shumel, B.
    Rossi, A. B.
    ALLERGY, 2020, 75 : 27 - 28
  • [43] Long-term dupilumab treatment up to 100 weeks has no impact on serum lipids in patients with moderate-to-severe atopic dermatitis
    Wollenberg, A.
    Bieber, T.
    Khokhar, F. A.
    Chen, Z.
    Shumel, B.
    Rossi, A. B.
    ALLERGY, 2020, 75 : 192 - 193
  • [44] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Xu, Xinghua
    Zheng, Yi
    Zhang, Xin
    He, Yanling
    Li, Chengxin
    ONCOTARGET, 2017, 8 (65) : 108480 - 108491
  • [45] Dupilumab treatment provides long-term improvement in itch in pediatric patients with moderate-to-severe atopic dermatitis over 1 year
    Siegfried, Elaine
    Simpson, Eric L.
    Boguniewicz, Mark
    Flohr, Carsten
    Eichenfield, Lawrence F.
    Pinter, Andreas
    Ramien, Michele
    Gao, Xing-Hua
    Chen, Zhen
    Bates, Lauren
    Rossi, Ana B.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II56 - II57
  • [46] Long-term dupilumab treatment up to 100 weeks reduces serum biomarkers in adult patients with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Thaci, D.
    Bissonnette, R.
    Deleuran, M.
    Bastian, M.
    Harel, S.
    Chen, Z.
    Levit, N. A.
    Rossi, A. B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 55 - 56
  • [47] Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
    Andreas Kuznik
    Gaëlle Bégo-Le-Bagousse
    Laurent Eckert
    Abhijit Gadkari
    Eric Simpson
    Christopher N. Graham
    LaStella Miles
    Vera Mastey
    Puneet Mahajan
    Sean D. Sullivan
    Dermatology and Therapy, 2017, 7 : 493 - 505
  • [48] Dupilumab in Combination With JAK Inhibitor for Refractory Moderate-to-Severe Atopic Dermatitis
    Song, Xiaoting
    Liu, Bo
    Peng, Chengyue
    Tan, Yen
    Zhao, Zuotao
    DERMATOLOGIC THERAPY, 2024, 2024 (01)
  • [49] A study into the drug dupilumab in Japanese adults with moderate-to-severe atopic dermatitis
    不详
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (01) : E4 - E4
  • [50] Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
    Kuznik, Andreas
    Bego-Le-Bagousse, Gaelle
    Eckert, Laurent
    Gadkari, Abhijit
    Simpson, Eric
    Graham, Christopher N.
    Miles, LaStella
    Mastey, Vera
    Mahajan, Puneet
    Sullivan, Sean D.
    DERMATOLOGY AND THERAPY, 2017, 7 (04) : 493 - 505
12345